Bausch Health Posts Mixed Q1 2026 Results Amid Goodwill Impairment
Event summary
- Bausch Health reported Q1 2026 revenues of $2.52 billion, up 12% year-over-year, with 7% organic growth.
- The company recorded a GAAP net loss of $1.423 billion, primarily due to a $1.426 million goodwill impairment charge.
- Adjusted EBITDA attributable to Bausch Health increased 27% to $837 million.
- Bausch Health excluding Bausch + Lomb delivered its twelfth consecutive quarter of year-over-year revenue and adjusted EBITDA growth.
- The company reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance.
The big picture
Bausch Health's Q1 2026 results highlight the company's ongoing efforts to drive sustainable performance and shareholder value, despite the significant goodwill impairment charge. The company's strategic priorities, including pipeline development and business development opportunities, are aligned with broader industry trends in pharmaceutical innovation and value creation. The reaffirmation of full-year guidance suggests confidence in the company's ability to navigate current challenges and capitalize on growth opportunities.
What we're watching
- Pipeline Progress
- The advancement of larsucosterol for alcohol-associated hepatitis and potential additional indications will be critical to watch.
- Segment Performance
- The ability of the Salix and Solta Medical segments to sustain their strong growth will be key indicators of the company's strategic execution.
- Debt Management
- The company's focus on strengthening its balance sheet and delivering value to shareholders amid its debt obligations will be an important factor to monitor.
Related topics